Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center – James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved EGFR tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Compared to gefitinib, dacomitinib had improved progression-free survival. However, due to the lower toxicity profile and overall survival data of osimertinib, Dr. Bertino believes dacomitinib, like erlotinib, gefitinib, and afatinib, may find its place as a second-line therapy.

Learn more by clicking here.